EGFR and neoplasm: Focal tissue sampling, however, fails to assess both the spatial and temporal tumor heterogeneity [17], while diverse prognosis to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) highlights the necessity of EGFR genotype stratification [18,19].